Headlands Technologies’s Acadia Pharmaceuticals ACAD Stock Holding History

Headlands Technologies’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$386K	Sell	15,273 -9,023	-37%	-$199K	0.04%	475
2026 Q1	$541K	Buy	+24,296	New	+$581K	0.06%	340
2025 Q2	–	Sell	-13,341	Closed	-$222K	–	1147
2025 Q1	$222K	Sell	13,341 -34,916	-72%	-$634K	0.03%	439
2024 Q4	$886K	Buy	48,257 +3,619	+8%	+$58.4K	0.09%	234
2024 Q3	$687K	Sell	44,638 -12,571	-22%	-$210K	0.08%	271
2024 Q2	$930K	Buy	57,209 +54,608	+2,100%	+$881K	0.1%	180
2024 Q1	$48.1K	Buy	+2,601	New	+$64.4K	0.01%	732
2023 Q3	–	Sell	-5,562	Closed	-$133K	–	890
2023 Q2	$133K	Buy	+5,562	New	+$124K	0.04%	342

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Headlands Technologies's ACAD Position: Q2 2026 in Review

Headlands Technologies reduced its Acadia Pharmaceuticals (ACAD) stake by 37% in Q2 2026, selling an estimated $199K and leaving 15,273 shares worth $386K. The position accounts for 0.04% of the portfolio, ranked #475.

Headlands Technologies first reported a position in ACAD in Q2 2023 and has held it in 8 quarters since. The position peaked at $930K in Q2 2024. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Headlands Technologies held 15,273 shares of Acadia Pharmaceuticals worth $386K as of Q2 2026.
Headlands Technologies sold 9,023 Acadia Pharmaceuticals shares in Q2 2026, an estimated $199K.
Acadia Pharmaceuticals made up 0.04% of Headlands Technologies's portfolio in Q2 2026, its #475 holding.
Headlands Technologies first reported a position in Acadia Pharmaceuticals in Q2 2023 and has held it in 8 quarters since.
Headlands Technologies's Acadia Pharmaceuticals position peaked at $930K in Q2 2024.
353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.